Genentech turns eye implant's focus to diabetes
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...
Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...
Wafaa Mamilli will join Roche as the company's new Chief Digital Technology Officer in February. This follows expansive roles ...
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...
San Francisco, California–based Genentech, has potent antitumor activity. More than half the patients with advanced and inoperable skin cancer treated with GDC-0449 responded to treatment (New Engl.
Since its founding in San Francisco in 1976, biotechnology pioneer Genentech has helped revolutionize the way doctors treat some of the world’s most complex health challenges, including the ...
Joshua Nair is a driven Principal Administrative Business Partner and Operations Manager at Genentech, with over a decade of ...
A four-year battle over one of the most ubiquitous patents in biotech ended with the US Patent and Trademark Office (USPTO) coming down on Genentech's side. The decision, reached in February ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback